Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Idexx Laboratories, Inc shares valued at $6,629,014 were sold by Hunt Nimrata on Nov 07 ’25. At $703.34 per share, Hunt Nimrata sold 9,425 shares. The insider’s holdings dropped to 21,149 shares worth approximately $14.73 million following the completion of this transaction.
Also, NIMRATA K HUNT purchased 9,425 shares, netting a total of over 6,629,060 in proceeds.
Before that, SZOSTAK M ANNE had sold 2,187 shares from its account. In a trade valued at $1,415,700, the Director traded Idexx Laboratories, Inc shares for $647.33 each. Upon closing the transaction, the insider’s holdings decreased to 2,187 shares, worth approximately $0.18 million.
As published in their initiating research note from Barclays on December 09, 2025, Idexx Laboratories, Inc [IDXX] has been an Overweight and the price target has been revised to $850. Analysts at Stifel upgraded the stock from ‘”a Hold”‘ to ‘”a Buy”‘ outlook in a report released in late October. As of October 01, 2025, UBS has initiated its “Neutral” rating for IDXX. Earlier on August 05, 2025, BTIG Research resumed its rating. Their recommendation was “a Buy” for IDXX stock.
Analyzing IDXX Stock Performance
On last trading session, Idexx Laboratories, Inc [NASDAQ: IDXX] rose 1.52% to $696.46. The stock’s lowest price that day was $681.0, but it reached a high of $709.235 in the same session. During the last five days, there has been a drop of approximately -2.46%. Over the course of the year, Idexx Laboratories, Inc shares have jumped approximately 66.12%.
Is Idexx Laboratories, Inc subject to short interest?
Stocks of Idexx Laboratories, Inc saw a sharp steep in short interest on 2025-12-31 dropping by -0.24 million shares to 1.98 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 2.22 million shares. A decline of -12.07% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 3.79 of the overall float, the days-to-cover ratio (short ratio) decline to 3.79.
Which companies own the most shares of Idexx Laboratories, Inc (IDXX)?
In terms of Idexx Laboratories, Inc share price expectations, FactSet research, analysts set an average price target of 805 in the next 12 months, up nearly 17.34% from the previous closing price of $686.02. Analysts anticipate Idexx Laboratories, Inc stock to reach 850 by 2026, with the lowest price target being 750. In spite of this, 6 analysts ranked Idexx Laboratories, Inc stock as Buy at the end of 2026. On July 01, 2025, Jefferies assigned a price target of “a Buy” to the stock and initiated coverage with a $625.
